Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Management identifies a compelling 'vintage' for new originations in the lower middle market as traditional banks and larger private credit funds retreat or move up-market.
The company is intentionally shifting its focus toward recession-resistant sectors like healthcare and insurance, moving away from the cyclicality and regulatory volatility of the cannabis industry. Performance attribution for the quarter was driven by modest increases in interest income, though total investment income declined due to the non-recurrence of a large $1.5 million exit fee from the prior period. Management emphasizes a disciplined underwriting approach that prioritizes senior secured first-lien positions with comprehensive maintenance covenants, contrasting this with 'covenant-light' trends in the upper middle market.
The legacy cannabis portfolio remains the primary source of non-accruals, with management actively pursuing a liquidation strategy through receiverships and asset sales to recover capital. Strategic capital allocation included a $2.8 million share repurchase program, which management noted was $0.17 accretive to net asset value per share. Management expects origination activity to remain 'lumpy and episodic' despite a robust $1.3 billion pipeline, as they prioritize deal quality over deployment speed.
The company intends to leverage its SEC co-investment relief order to participate in larger transactions alongside affiliates, providing flexibility beyond its own balance sheet constraints. Liquidation of legacy assets, specifically the Devi and DMA positions, is expected to conclude within the 2026 calendar year, providing further capital for redeployment. Management is targeting an intermediate net debt-to-equity ratio of approximately 1.0x, indicating significant room for leverage expansion from the current 0.53x level.
Future deployments will focus on cash-flowing borrowers with EBITDA between $5 million and $50 million, primarily within sponsored transactions. The Justice Grown loan is in maturity default as of May 1, 2026; management has commenced Article 9 foreclosures and engaged advisors to market the underlying assets. Management expressed continued caution regarding the cannabis sector, citing a critical lack of available equity capital which hinders the 'refi-ability' of borrowers despite federal rescheduling progress.
A $1.1 million decline in total investment income quarter-over-quarter was attributed to the absence of one-time fees, highlighting the impact of episodic income on headline metrics. The Devi liquidation involves a binding term sheet for $12.5 million in cash proceeds, with a $2 million non-refundable deposit already secured subsequent to quarter-end. Nvidia-level potential. 30M+ investors trust Moby to find it first.
Extract — continue reading at the source.
